ALPHAMAB-B Buys Back 35,000 Shares, Lifts Treasury Stock to 7.75 Million

Bulletin Express

Sep 25

Alphamab Oncology (ALPHAMAB-B) disclosed a small-scale share repurchase executed on 25 September 2026 under its existing buyback mandate.

• Transaction details: 35,000 ordinary shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 8.20 to HKD 8.34, representing a volume-weighted average of HKD 8.29. Total consideration amounted to HKD 0.29 million.

• Capital structure impact: – Issued shares (excluding treasury shares) declined 0.0036% to 966.63 million. – Treasury shares rose to 7.75 million, while total issued shares stayed unchanged at 974.38 million.

• Mandate utilisation: Since shareholders approved a 96.85 million-share buyback authority on 12 June 2026, Alphamab has repurchased 1.87 million shares, equating to 0.19% of the issued share count at the mandate date.

• Post-repurchase restriction: In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 25 October 2026.

The company confirmed that all repurchases complied with Main Board Rule 10.06 and that no changes have been made to the explanatory statement filed in May 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1117602364"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117602364\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117602364?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 20:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117602364","market":"us","top_or_hot":-1,"title":"ALPHAMAB-B Buys Back 35,000 Shares, Lifts Treasury Stock to 7.75 Million","media":"Bulletin Express","content":"<p>Alphamab Oncology (ALPHAMAB-B) disclosed a small-scale share repurchase executed on 25 September 2026 under its existing buyback mandate.</p>\n<p>• Transaction details: 35,000 ordinary shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 8.20 to HKD 8.34, representing a volume-weighted average of HKD 8.29. Total consideration amounted to HKD 0.29 million.</p>\n<p>• Capital structure impact:  \n  – Issued shares (excluding treasury shares) declined 0.0036% to 966.63 million.  \n  – Treasury shares rose to 7.75 million, while total issued shares stayed unchanged at 974.38 million.</p>\n<p>• Mandate utilisation: Since shareholders approved a 96.85 million-share buyback authority on 12 June 2026, Alphamab has repurchased 1.87 million shares, equating to 0.19% of the issued share count at the mandate date.</p>\n<p>• Post-repurchase restriction: In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 25 October 2026.</p>\n<p>The company confirmed that all repurchases complied with Main Board Rule 10.06 and that no changes have been made to the explanatory statement filed in May 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALPHAMAB-B Buys Back 35,000 Shares, Lifts Treasury Stock to 7.75 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALPHAMAB-B Buys Back 35,000 Shares, Lifts Treasury Stock to 7.75 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-25 20:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Alphamab Oncology (ALPHAMAB-B) disclosed a small-scale share repurchase executed on 25 September 2026 under its existing buyback mandate.</p>\n<p>• Transaction details: 35,000 ordinary shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 8.20 to HKD 8.34, representing a volume-weighted average of HKD 8.29. Total consideration amounted to HKD 0.29 million.</p>\n<p>• Capital structure impact:  \n  – Issued shares (excluding treasury shares) declined 0.0036% to 966.63 million.  \n  – Treasury shares rose to 7.75 million, while total issued shares stayed unchanged at 974.38 million.</p>\n<p>• Mandate utilisation: Since shareholders approved a 96.85 million-share buyback authority on 12 June 2026, Alphamab has repurchased 1.87 million shares, equating to 0.19% of the issued share count at the mandate date.</p>\n<p>• Post-repurchase restriction: In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 25 October 2026.</p>\n<p>The company confirmed that all repurchases complied with Main Board Rule 10.06 and that no changes have been made to the explanatory statement filed in May 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09966","symbol_name":"康宁杰瑞制药-B","start_time":0,"source_url":"","article_id":"1117602364","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117602364","pubTimestamp":1790340211,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Alphamab Oncology (ALPHAMAB-B) disclosed a small-scale share repurchase executed on 25 September 2026 under its existing buyback mandate. • Transaction details: 35,000 ordinary shares were bought on...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09966":"康宁杰瑞制药-B"},"translate_title":"ALPHAMAB-B 回购 35,000 股股票，库存股增至 775 万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09966":1},"content_text":"Alphamab Oncology (ALPHAMAB-B) disclosed a small-scale share repurchase executed on 25 September 2026 under its existing buyback mandate.\n• Transaction details: 35,000 ordinary shares were bought on the Hong Kong Stock Exchange at prices ranging from HKD 8.20 to HKD 8.34, representing a volume-weighted average of HKD 8.29. Total consideration amounted to HKD 0.29 million.\n• Capital structure impact:  \n  – Issued shares (excluding treasury shares) declined 0.0036% to 966.63 million.  \n  – Treasury shares rose to 7.75 million, while total issued shares stayed unchanged at 974.38 million.\n• Mandate utilisation: Since shareholders approved a 96.85 million-share buyback authority on 12 June 2026, Alphamab has repurchased 1.87 million shares, equating to 0.19% of the issued share count at the mandate date.\n• Post-repurchase restriction: In line with Hong Kong listing rules, the company is restricted from issuing new shares or disposing of treasury shares until 25 October 2026.\nThe company confirmed that all repurchases complied with Main Board Rule 10.06 and that no changes have been made to the explanatory statement filed in May 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}